Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Bridgebio Pharma Inc (NQ: BBIO )

28.16 +0.46 (+1.66%)
Streaming Delayed Price Updated: 11:51 AM EDT, May 9, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Bridgebio Pharma Inc

< Previous 1 2 3 Next >
BridgeBio and Resilience Announce Strategic Multi-Year Partnership to Advance BBP-631, BBP-812 and Future Gene Therapy Treatments
From BridgeBio Pharma, Inc.
Via GlobeNewswire
BridgeBio Pharma Announces $250 Million Private Placement Equity Financing
From BridgeBio Pharma, Inc.
Via GlobeNewswire
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
From BridgeBio Pharma, Inc.
Via GlobeNewswire
BridgeBio Pharma Inc. (NASDAQ: BBIO) is a Stock Spotlight on 8/18
Via Investor Brand Network
BridgeBio Pharma to Participate in the Morgan Stanley 21st Annual Global Healthcare Conference
From BridgeBio Pharma, Inc.
Via GlobeNewswire
BridgeBio Pharma Announces Positive Feedback from the U.S. FDA and EU EMA on the Regulatory Path for a Pivotal Phase 3 Trial of Infigratinib in Children with Achondroplasia
From BridgeBio Pharma, Inc.
Via GlobeNewswire
BridgeBio presents detailed positive results from Phase 3 ATTRibute-CM study of acoramidis for patients with transthyretin amyloid cardiomyopathy (ATTR-CM) at European Society of Cardiology Congress 2023
From BridgeBio Pharma, Inc.
Via GlobeNewswire
BridgeBio Pharma to Present Detailed Results from the Phase 3 ATTRibute Study in Patients with Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM) at European Society of Cardiology (ESC) Congress 2023
From BridgeBio Pharma, Inc.
Via GlobeNewswire
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
From BridgeBio Pharma, Inc.
Via GlobeNewswire
BridgeBio Pharma Reports Second Quarter 2023 Financial Results and Business Update
From BridgeBio Pharma, Inc.
Via GlobeNewswire
BridgeBio Pharma Announces Opportunity for Accelerated Approval Pathway in Limb-girdle Muscular Dystrophy Type 2I (LGMD2I/R9) Based on Glycosylated Alpha-dystroglycan (⍺DG) Levels and Announces First Patient Dosed in FORTIFY Phase 3 Study
From BridgeBio Pharma, Inc.
Via GlobeNewswire
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
From BridgeBio Pharma, Inc.
Via GlobeNewswire
BridgeBio (NASDAQ: BBIO) Announces Exceptionally Positive Outcomes in Phase 3 Study of Acoramidis
BridgeBio Pharma (NASDAQ: BBIO), a leading biopharmaceutical company, announced significant outcomes from the ATTRibute-CM, their Phase 3 study of acoramidis, 
Via Spotlight Growth
BridgeBio Pharma Inc. (NASDAQ: BBIO) Records 52-Week High Monday Morning
Via Investor Brand Network
BridgeBio announces consistently positive results from Phase 3 ATTRibute-CM study of acoramidis for patients with transthyretin amyloid cardiomyopathy (ATTR-CM)
From BridgeBio Pharma, Inc.
Via GlobeNewswire
BridgeBio to Host Investor Call to Share Topline 30-month Results from the Phase 3 ATTRibute-CM Study in Patients with Transthyretin Amyloid Cardiomyopathy on July 17, 2023
From BridgeBio Pharma, Inc.
Via GlobeNewswire
Burjeel Holdings to Launch Rare Disease Research & Development Project ‘NADER’ in Partnership with US-based BridgeBio Pharma
From BridgeBio Pharma, Inc.
Via GlobeNewswire
BridgeBio Pharma Presents Updated Six Month Results from its Phase 2 Cohort 5 Trial of Infigratinib in Achondroplasia at the Endocrine Society (ENDO) 2023 Annual Conference
From BridgeBio Pharma, Inc.
Via GlobeNewswire
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
From BridgeBio Pharma, Inc.
Via GlobeNewswire
BridgeBio Pharma to Present Updated Six Month Results from its Phase 2 Cohort 5 Study of Infigratinib in Achondroplasia in a Late Breaker Oral Presentation at the Endocrine Society (ENDO) 2023 Annual Conference
From BridgeBio Pharma, Inc.
Via GlobeNewswire
BridgeBio Pharma Presents Updated Encouraging Clinical and Biomarker Data from its BBP-812 Canavan Disease Gene Therapy Program at the 2023 American Society of Gene and Cell Therapy (ASGCT) Annual Meeting
From BridgeBio Pharma, Inc.
Via GlobeNewswire
BridgeBio Pharma to Present Updated Data from its BBP-812 Canavan Disease Gene Therapy Program at the 2023 American Society of Gene and Cell Therapy (ASGCT) Annual Meeting
From BridgeBio Pharma, Inc.
Via GlobeNewswire
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
From BridgeBio Pharma, Inc.
Via GlobeNewswire
BridgeBio Pharma Reports First Quarter 2023 Financial Results and Business Update
From BridgeBio Pharma, Inc.
Via GlobeNewswire
BridgeBio Pharma to Participate in the Bank of America Merrill Lynch Global Healthcare Conference
From BridgeBio Pharma, Inc.
Via GlobeNewswire
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
From BridgeBio Pharma, Inc.
Via GlobeNewswire
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
From BridgeBio Pharma, Inc.
Via GlobeNewswire
BridgeBio Pharma Announces First Lung Cancer Patient Dosed in Phase 1 Trial for SHP2 Inhibitor BBP-398 in Combination with Bristol Myers Squibb’s OPDIVO® (nivolumab)
From BridgeBio Pharma, Inc.
Via GlobeNewswire
BridgeBio Pharma Shares Preliminary Findings on Novel Bioassay Measuring Glycosylated Alpha-dystroglycan (⍺DG) in Patients with Limb-girdle Muscular Dystrophy Type 2I (LGMD2I)
From BridgeBio Pharma, Inc.
Via GlobeNewswire
BridgeBio Pharma to Present Preliminary Findings on its Novel Bioassay Measuring Glycosylated Alpha-dystroglycan (⍺DG) in Patients with Limb-girdle Muscular Dystrophy Type 2I (LGMD2I)
From BridgeBio Pharma, Inc.
Via GlobeNewswire
< Previous 1 2 3 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.